PT  - JOURNAL ARTICLE
AU  - González-Gay, Miguel Ángel
AU  - Castañeda, Santos
AU  - Ferraz-Amaro, Iván
TI  - Managing Giant Cell Arteritis With Tocilizumab: Relapses and Adverse Events
AID  - 10.3899/jrheum.2024-1204
DP  - 2024 Dec 15
TA  - The Journal of Rheumatology
PG  - jrheum.2024-1204
4099  - http://www.jrheum.org/content/early/2024/12/07/jrheum.2024-1204.short
4100  - http://www.jrheum.org/content/early/2024/12/07/jrheum.2024-1204.full
AB  - In this issue of The Journal of Rheumatology, Nagase et al assessed the 2-year effectiveness and safety of tocilizumab (TCZ) in treating Japanese patients with giant cell arteritis (GCA) in real-world settings.1TCZ targets interleukin 6 (IL-6), a key cytokine involved in the inflammatory processes of GCA. Both open-label studies reflecting daily clinical practice2,3 and controlled trials4,5 have shown the effectiveness of TCZ in managing GCA in patients from Western countries.